In both models, adoptive transfer of CD123-ENG T-cells and CD123-ENG.IL15 T-cells significantly delayed AML progression, resulting in a significant survival advantage (Figures 4C, D), and CD123-ENG.IL15 T-cells dose-dependently had greater antitumor activity than CD123-ENG T-cells. This evidence concerns the gene IL15 and acute myeloid leukemia.